Eurofins Genomics and Weatherbys Ireland Join Forces to Genotype One Million Cattle
January 07 2016 - 1:00AM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), one of the world leaders in
genomic services, and Weatherbys Ireland DNA Laboratories, one of
Ireland’s premier laboratories serving the domestic agri-industry,
are pleased to announce that they have been jointly selected to
test one million samples of beef for the Irish Cattle Breeding
Federation (ICBF) over the next two years.
The ambitious project is the first anywhere in the world to
genotype one million cattle. The test itself uses a microarray
technology to measure 55,000 variable positions in the DNA of each
animal. From this, scientists will use this information to predict
traits such as fertility, milk yield and meat quality in individual
animals. The work is part of the Beef Data Genomics Program (BDGP),
running from 2015 to 2020, launched earlier this year by Ireland’s
Minister for Agriculture Food and Marine, Simon Coveney, TD. The
ICBF is aiming to genotype one million cattle by 2017, and a
further million by 2020.
Comment from Ronan Murphy, Weatherbys CEO: “This project is a
huge step forward in agri-genomics and we are delighted to have
been selected to carry out a testing regime that has never been
done on this scale before. The microarray chip we will be using has
taken two years of development by Weatherbys Ireland DNA
laboratory, the ICBF and Teagasc (Irish agriculture and food
development authority). By teaming up with Eurofins Genomics, we
are able to provide expertise and accredited laboratories at the
scale needed to provide customers with new and more efficient
services for their animal breeding needs.”
Comment from Bruno Poddevin, Senior Vice President, Eurofins
Genomic Services: “Eurofins Genomics is proud and delighted to have
been selected, together with Weatherbys’ DNA Laboratory, to provide
its expertise in the world’s largest cattle genotyping
project-to-date. Through our combined industrial capabilities and
highly-skilled DNA experts, Eurofins aims to provide customers in
the food and agri-genomics markets the highest quality and most
cost-efficient solutions for their animal-breeding needs. We are
excited to provide our unparalleled capabilities and lend our
expertise in large-scale project, and help put Ireland and its
farmers at the forefront of genetic testing globally”.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With 20,000 staff in around 200 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products, as well as for innovative clinical
diagnostic. The Group provides its customers with high-quality
services, accurate results on time and expert advice by its highly
qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients' increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the data
available to the Company as of the date of publication, but no
guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160106006504/en/
Eurofins GenomicsNicolas Rouquet, +33 6 80 22 00
93nicolasrouquet@eurofins.comorWeatherbys Ireland DNA LabRomy
Morrin O Donnell, +353 45 875 521rmorrin@weatherbys.ieorICBFLaura
Cullinane, +44 207 758 3900Laurac@launchpr.co.uk
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024